BEIGENE(06160),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

06160 BEIGENE

Market Closed 11-15 16:08:33

113.900

-1.300

-1.13%

High117.600	Low113.500	Vol1.10M
Open115.500	D1 Closing115.200	Amplitude3.56%
Mkt Cap157.07B	Tradable Cap143.97B	Total Shares1.38B
T/O126.59M	T/O Rate0.09%	Tradable Shares1.26B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"BEIGENE","latestPrice":113.9,"timestamp":1731658113020,"preClose":115.2,"halted":0,"volume":1104827,"delay":0,"floatShares":1264000000,"shares":1378992949,"eps":-0.6987122312992432,"marketStatus":"Market Closed","change":-1.3,"latestTime":"11-15 16:08:33","open":115.5,"high":117.6,"low":113.5,"amount":126587503,"amplitude":0.03559,"askPrice":113.9,"askSize":8200,"bidPrice":113.8,"bidSize":33900,"shortable":3,"etf":0,"ttmEps":-4.750315328983838,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1731893400000},"marketStatusCode":7,"adr":0,"listingDate":1533657600000,"exchange":"SEHK","adjPreClose":115.2,"openAndCloseTimeList":[[1731634200000,1731643200000],[1731646800000,1731657600000]],"volumeRatio":0.5543423897572256,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"Beigene,Ltd.","latestPrice":165.32,"timestamp":1731654000000,"preClose":168.82,"halted":0,"volume":1979800,"delay":0,"premium":"-35.93"}},"requestUrl":"/m/hq/s/06160/wiki","defaultTab":"wiki","newsList":[{"id":"2483794568","title":"BeiGene Proposes Name Change","url":"https://stock-news.laohu8.com/highlight/detail?id=2483794568","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483794568?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:15","pubTimestamp":1731586527,"startTime":"0","endTime":"0","summary":"BeiGene  is proposing to change its English name to BeOne Medicines, while keeping its Chinese name unchanged, a Thursday bourse filing said.The proposal comes about in order to reaffirm the drugmaker's commitment to develop innovative medicines to eliminate cancer by partnering with the global community and treat as many patients as possible.The name change is subject to shareholder and regulatory approvals.Hong Kong-listed shares of the company closed over 3% lower on Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4548","BK1161","BK4588","LU0588546209.SGD","688235","BK4505","BK4526","LU1969619763.USD","BK4585","BK1583","BK4535","BGNE","BK0239","BK4139","BK1588","BK1500","LU2328871848.SGD","06160","BK4504","LU0307460666.USD"],"gpt_icon":0},{"id":"2483879852","title":"BeiGene to Rename as BeOne Medicines","url":"https://stock-news.laohu8.com/highlight/detail?id=2483879852","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483879852?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:08","pubTimestamp":1731586083,"startTime":"0","endTime":"0","summary":"BeiGene  said Thursday it plans to change its name to BeOne Medicines, subject to shareholder approval.Once the name change is approved, the company's Nasdaq ticker will change to \"ONC.\"The name change is part of the company's global oncology growth strategy.Price: 222.99, Change: -4.06, Percent Change: -1.79","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4505","BK4526","BK4139","BK4548","BK4585","BK4588","06160","NQmain","BK4504","BK4535","MDCO","BGNE"],"gpt_icon":0},{"id":"2483188080","title":"BeiGene Swings to Loss in Q3; Hong Kong Shares Slide 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483188080","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483188080?lang=en_us&edition=fundamental","pubTime":"2024-11-13 10:10","pubTimestamp":1731463856,"startTime":"0","endTime":"0","summary":"BeiGene  swung to a net loss of $121.4 million in the third quarter from a profit of $215.4 million in the year-ago period.The drugmaker incurred a loss per share of $0.09, reversing earnings per share of $0.15 in the previous year, according to a Wednesday filing with the Hong Kong Exchange.Total revenue jumped to $1 billion from $781.3 million a year earlier, driven by growth in BRUKINSA product sales in the US and Europe.Shares slid 3% in Hong Kong during Wednesday's morning trading.Price : $116.90, Change: $-4.9, Percent Change: -4.02%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0588546209.SGD","BK4548","LU2328871848.SGD","BK4139","BK1161","688235","BK4023","BK1588","BK4504","BK4535","HKD","BK4585","BK1583","LU1969619763.USD","BK1500","BK0239","BGNE","BK4526","LU0307460666.USD","06160","BK4588","BK4505"],"gpt_icon":0},{"id":"2482635770","title":"BeiGene Swings to Q3 Net Loss, Revenue Rises","url":"https://stock-news.laohu8.com/highlight/detail?id=2482635770","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482635770?lang=en_us&edition=fundamental","pubTime":"2024-11-12 19:43","pubTimestamp":1731411798,"startTime":"0","endTime":"0","summary":"BeiGene Ltd  reported a Q3 net loss Tuesday of $1.15 per American depositary share, swinging from earnings of $2.01 a year earlier.Analysts polled by Capital IQ expected a loss of $0.99.Revenue for the quarter ended Sept. 30 was $1 billion, up from $781.3 million a year earlier.Analysts surveyed by Capital IQ expected $984.2 million.Price: 222.99, Change: -4.06, Percent Change: -1.79","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BGNE","06160"],"gpt_icon":0},{"id":"1113508179","title":"Stock Track | BeiGene Stock Plunges After Reporting Hefty Q3 Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1113508179","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113508179?lang=en_us&edition=fundamental","pubTime":"2024-11-12 19:18","pubTimestamp":1731410314,"startTime":"0","endTime":"0","summary":"Shares of BeiGene Ltd, a biotechnology company focused on developing innovative anti-cancer drugs, plummeted by 5.11% on November 12th, following the release of its third-quarter financial results.The company reported a staggering net loss of 809.3 million yuan  for the quarter ended September 30th. This substantial loss likely spooked investors, contributing to the sharp decline in BeiGene's stock price.BeiGene's disappointing financial performance can be attributed to the significant costs ass","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["06160"],"gpt_icon":0},{"id":"2482729327","title":"BRIEF-BeiGene's Q3 Net Loss 809.3 Mln Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2482729327","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482729327?lang=en_us&edition=fundamental","pubTime":"2024-11-12 19:16","pubTimestamp":1731410200,"startTime":"0","endTime":"0","summary":"Nov 12 (Reuters) - Beigene Ltd   :   * SAYS Q3 NET LOSS AT 809.3 MILLION YUAN ($111.85 million)    Source text  Further company coverage:   ($1 = 7.2353 Chinese yuan renminbi) (Reporting by Beijing newsroom)((Ella.Cao@thomsonreuters.com;))","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","BK1161","LU0588546209.SGD","BK1588","LU2328871848.SGD","LU0307460666.USD","BK1583","BK1500","LU1969619763.USD"],"gpt_icon":0},{"id":"2482772675","title":"BeiGene Q3 2024 GAAP EPADS $(1.15) Beats $(1.20) Estimate, Sales $1.00B Beat $979.78M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2482772675","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482772675?lang=en_us&edition=fundamental","pubTime":"2024-11-12 19:12","pubTimestamp":1731409938,"startTime":"0","endTime":"0","summary":"BeiGene (NASDAQ:BGNE) reported quarterly losses of $(1.15) per share which beat the analyst consensus estimate of $(1.20) by 4.17 percent.  The company reported quarterly sales of $1.00 billion which beat the analyst","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41895346/beigene-q3-2024-gaap-epads-1-15-beats-1-20-estimate-sales-1-00b-beat-979-78m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BeiGene Q3 2024 GAAP EPADS $(1.15) Beats $(1.20) Estimate, Sales $1.00B Beat $979.78M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","BGNE"],"gpt_icon":0},{"id":"2477262369","title":"Indaptus Therapeutics Shares Rise After Pact to Develop Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2477262369","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477262369?lang=en_us&edition=fundamental","pubTime":"2024-10-23 02:24","pubTimestamp":1729621440,"startTime":"0","endTime":"0","summary":"Shares of Indaptus Therapeutics rose after the company said it reached an agreement with BeiGene to evaluate novel cancer treatment combinations.The stock gained 14% to $1.68 in afternoon trading Tuesday. Shares are down 6.8% since the beginning of the year.Under Indaptus' clinical supply agreement with BeiGene, the New York biotechnology company plans to advance human clinical evaluation of its cancer treatment -- called Decoy20, which is being studied as a treatment for various cancers, such as liver, colon and pancreatic -- in combination with BeiGene's anti-PD-1 antibody, called tislelizumab.Preclinical studies showed that Decoy20, when used in combination with a PD-1 inhibitor and an oral non-steroidal anti-inflammatory agent, demonstrated tumor eradication rates of between 80% and 100%, Indaptus said.Terms of the agreement weren't disclosed. As part of the pact, BeiGene will provide Indaptus with access to its PD-1 inhibitor, as well as provide technical expertise to accelerate t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","BK4505","BK4526","LENZ","BK4585","BK1588","INDP","BK1161","BK1500","BK4548","LU2328871848.SGD","BK1583","LU1969619763.USD","BK4504","LU0307460666.USD","BGNE","BK4588","BK4535","LU0588546209.SGD","BK4139"],"gpt_icon":0},{"id":"2477583343","title":"Indaptus Therapeutics signs clinical supply agreement with Beigene","url":"https://stock-news.laohu8.com/highlight/detail?id=2477583343","media":"seekingalpha","labels":["Company Corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477583343?lang=en_us&edition=fundamental","pubTime":"2024-10-22 21:34","pubTimestamp":1729604059,"startTime":"0","endTime":"0","summary":"Eoneren/E+ via Getty Images  Indaptus Therapeutics  announced a clinical supply agreement with BeiGene  . Indaptus plans to advance human clinical evaluation of the combination of BeiGene's anti-PD-1 antibody, tislelizumab, with Indaptus’ Decoy20, a novel treatment designed to induce a broad immune response to fight cancer.","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1346213103/image_1346213103.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1346213103/image_1346213103.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4189766-indaptus-therapeutics-signs-clinical-supply-agreement-with-beigene","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Company Corporation","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BK4139","BK4526","BK4548","BK1583","PSQ","SQQQ","TQQQ","06160","LENZ","BK4504","BK1161","LU0307460666.USD","BK4535","INDP","BK4588","BK1500","NQmain","LU2328871848.SGD","LU0588546209.SGD",".IXIC","QID","BGNE","BK4585","LU1969619763.USD","BK4505","BK1588","QLD","MNQmain"],"gpt_icon":0},{"id":"2477335593","title":"Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations","url":"https://stock-news.laohu8.com/highlight/detail?id=2477335593","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477335593?lang=en_us&edition=fundamental","pubTime":"2024-10-22 20:00","pubTimestamp":1729598400,"startTime":"0","endTime":"0","summary":"Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus’ broadly targeted, short duration systemic immune stimulator Decoy20 expected to start in 2025","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/22/2966888/0/en/Indaptus-Therapeutics-Announces-Clinical-Supply-Agreement-with-BeiGene-to-Evaluate-Novel-Cancer-Treatment-Combinations.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NLR","06160","BGNE","BK4139","LENZ"],"gpt_icon":0},{"id":"2477852205","title":"BeiGene's Stomach, Esophageal Cancer Drug Receives Positive European Committee Opinions","url":"https://stock-news.laohu8.com/highlight/detail?id=2477852205","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477852205?lang=en_us&edition=fundamental","pubTime":"2024-10-21 20:42","pubTimestamp":1729514563,"startTime":"0","endTime":"0","summary":"BeiGene  said Monday that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued positive opinions recommending an extended authorization for Tevimbra  in gastric or gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.The recommendations were based on two clinical trials showing that the drug, in combination with chemotherapy, \"improved survival compared to treatment with a placebo plus chemotherapy,\" said Florian Lordick, director and professor of oncology at the University Cancer Center in Leipzig.BeiGene shares were 0.5% higher in recent premarket trading.Price: 220.00, Change: +1.03, Percent Change: +0.47","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK4585","06160","BK1583","LU0307460666.USD","BK4505","BK4588","BK4526","LU1969619763.USD","BK4504","BK4535","LU0588546209.SGD","BK1588","BK4139","BGNE","BK1500","BK4548","LU2328871848.SGD"],"gpt_icon":0},{"id":"2477326858","title":"Nomura Raises Price Target on BeiGene to $293.78 From $266, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2477326858","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477326858?lang=en_us&edition=fundamental","pubTime":"2024-10-21 18:43","pubTimestamp":1729507380,"startTime":"0","endTime":"0","summary":"BeiGene (BGNE) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $152 to $345.(MT Newswires covers equity, commodity and economic research fr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BGNE","NMR","06160"],"gpt_icon":0},{"id":"2477783990","title":"Nomura Adjusts BeiGene's Price Target to HK$174.91 From HK$158.37, Keeps at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2477783990","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477783990?lang=en_us&edition=fundamental","pubTime":"2024-10-21 17:19","pubTimestamp":1729502383,"startTime":"0","endTime":"0","summary":"Nomura Adjusts BeiGene's Price Target to HK$174.91 From HK$158.37, Keeps at Buy","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06160","BGNE","NMR"],"gpt_icon":0},{"id":"1185404173","title":"Stock Track | BeiGene Plunges 8% Amid Hong Kong Market Rout on Stimulus Uncertainty","url":"https://stock-news.laohu8.com/highlight/detail?id=1185404173","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1185404173?lang=en_us&edition=fundamental","pubTime":"2024-10-14 16:43","pubTimestamp":1728895398,"startTime":"0","endTime":"0","summary":"Shares of BeiGene, a leading biopharmaceutical company based in Beijing, tumbled nearly 8.5% on Monday, mirroring the broader market selloff in Hong Kong amid growing uncertainty over the scale and timing of further economic stimulus measures from Chinese authorities.The Hang Seng Index, Hong Kong's benchmark, fell 0.75% as investors were left disappointed after China's finance minister, Lan Foan, hinted at significantly increasing debt but failed to provide specific details on the size of the s","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["06160"],"gpt_icon":0},{"id":"2475337841","title":"Hong Kong Stocks Fall on Uncertainty in Further Stimulus; Pharma Firms Lead Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2475337841","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475337841?lang=en_us&edition=fundamental","pubTime":"2024-10-14 16:39","pubTimestamp":1728895199,"startTime":"0","endTime":"0","summary":"Hong Kong stocks fell on Monday following a holiday as investor sentiment waned after China's finance ministry failed to specify further stimulus measures for the economy.The Hang Seng Index fell 0.75","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["82020","LU2476274308.USD","SG9999014674.SGD","LU0823426308.USD","02020","LU1008478684.HKD","BK0155","01801","81211","EVS.SI","MCHmain","02833","LU0594300419.USD","06160","IE00B031J352.USD","SG9999006514.SGD","BK1509","BK1589","LU2360107325.USD","513600","LU0359201612.USD","BK1227","BK1588","SG9999006597.SGD","01211","LU0320764599.SGD","688235","BYDDY","BK1168","LU0289961442.SGD","IE00B031HY20.USD","BK1583","HSI","LU1868838027.USD","LU1861219969.SGD","LU0261947096.USD","IE0008369823.USD","BK0169","LU0052750758.USD","ANPDY","LU0048597586.USD","LU0143863198.USD","LU1152091754.HKD","LU1226288170.HKD","LU0605514214.HKD","IE0031814852.USD","SG9999015952.SGD","HHImain","01093"],"gpt_icon":1},{"id":"2472672796","title":"BeiGene Grants Options, Restricted Share Units to Employees","url":"https://stock-news.laohu8.com/highlight/detail?id=2472672796","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472672796?lang=en_us&edition=fundamental","pubTime":"2024-10-04 09:28","pubTimestamp":1728005293,"startTime":"0","endTime":"0","summary":"BeiGene  granted share options and restricted share units to its employees and directors under its 2016 share option and incentive plan, according to a Friday filing with the Hong Kong stock exchange.The biopharmaceutical company granted 22,713 American depositary shares to 12 employees.The options are equivalent to 295,269 underlying shares, and will vest in 10 years, the filing said.It also granted 90,542 restricted share units in ADSs to 223 recipients, equivalent to 1,177,046 underlying shares, according to the filing.Price : $147.70, Change: $+7.0, Percent Change: +4.98%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2328871848.SGD","LU0307460666.USD","BK4139","BK4585","BK4588","BK0239","BK1161","BK1588","BK4526","BK4504","688235","BGNE","BK4023","BK4505","BK4548","BK1500","BK4535","06160","LU1969619763.USD","BK1583","LU0588546209.SGD"],"gpt_icon":1},{"id":"2471876952","title":"JPMorgan Chase & Co's Long Position in Beigene  Decreases to 8.83% on Sept 24 From 10.03% - HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2471876952","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471876952?lang=en_us&edition=fundamental","pubTime":"2024-09-30 17:12","pubTimestamp":1727687528,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240930:nFWN3LC0EL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK0239","688235","BK1588","LU1969619763.USD","BK1500","BK1583","LU2328871848.SGD","BK1161","LU0307460666.USD","06160","LU0588546209.SGD"],"gpt_icon":0},{"id":"1186523930","title":"Stock Track | BeiGene Soars 6% After FDA Boosts Prospects for Key Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1186523930","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186523930?lang=en_us&edition=fundamental","pubTime":"2024-09-27 18:42","pubTimestamp":1727433756,"startTime":"0","endTime":"0","summary":"Shares of BeiGene  surged 6% on Thursday after the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee recognized the \"favorable benefit-risk profile\" of PD-1 inhibitors like the company's Tevimbra cancer treatment.The FDA advisory committee's conclusion applied to the use of PD-1 inhibitors as a first-line treatment for patients with locally advanced inoperable or metastatic esophageal squamous cell carcinoma expressing certain specific cancer markers. The positive assessment","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["06160"],"gpt_icon":0},{"id":"2470058037","title":"BeiGene Shares Climb Pre-Bell After FDA Gives Favorable Opinion on Class of Cancer Treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2470058037","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470058037?lang=en_us&edition=fundamental","pubTime":"2024-09-27 18:40","pubTimestamp":1727433640,"startTime":"0","endTime":"0","summary":"BeiGene  shares were up 3.5% in Friday's premarket activity after it said that the US Food and Drug Administration's Oncologic Drugs Advisory Committee had recognized the \"favorable benefit-risk profile\" of PD-1 inhibitors such as the company's Tevimbra as a first-line treatment for patients with locally advanced inoperable or metastatic esophageal squamous cell carcinoma.The conclusion by the advisory applied to esophageal squamous cell carcinoma expressing certain specific cancer markers, the company said. It was based on several studies of PD-1 inhibitors, including Tevimbra, also called tislelizumab-jsgr.The company said the Biologics License Applications for Tevimbra remain under FDA review. The drug has already been approved in the US for the treatment of adults with unresectable or metastatic ESCC after prior chemotherapy treatments.Price: 220.01, Change: +7.48, Percent Change: +3.52","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1588","BK4526","BK4588","LU0588546209.SGD","BK4535","BK4504","BK4585","BK4548","LU1969619763.USD","06160","BK4505","BK1161","LU0307460666.USD","BK1583","BK1500","BGNE","BK4139","LU2328871848.SGD"],"gpt_icon":0},{"id":"2470799943","title":"Beigene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of Pd-1 Inhibitors, Including Tevimbra®, for Treatment of Escc and Gastric/Gej Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2470799943","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470799943?lang=en_us&edition=fundamental","pubTime":"2024-09-27 06:21","pubTimestamp":1727389260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240926:nTUA4ZSP2Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1588","LU0588546209.SGD","LU1969619763.USD","06160","LU0307460666.USD","BK1161","BK1583","BK1500","LU2328871848.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.beigene.cn","stockEarnings":[{"period":"1week","weight":-0.0755},{"period":"1month","weight":-0.15},{"period":"3month","weight":-0.0347},{"period":"6month","weight":0.0994},{"period":"1year","weight":-0.0139},{"period":"ytd","weight":0.0345}],"compareEarnings":[{"period":"1week","weight":-0.0628},{"period":"1month","weight":-0.0424},{"period":"3month","weight":0.1145},{"period":"6month","weight":-0.0065},{"period":"1year","weight":0.0894},{"period":"ytd","weight":0.1395}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.03281},{"month":2,"riseRate":0.5,"avgChangeRate":0.020001},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.060772},{"month":4,"riseRate":0.5,"avgChangeRate":0.051983},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.053583},{"month":6,"riseRate":0.5,"avgChangeRate":0.011188},{"month":7,"riseRate":0.833333,"avgChangeRate":0.075403},{"month":8,"riseRate":0.833333,"avgChangeRate":0.065797},{"month":9,"riseRate":0.428571,"avgChangeRate":0.01247},{"month":10,"riseRate":0.571429,"avgChangeRate":-0.017395},{"month":11,"riseRate":0.428571,"avgChangeRate":0.102981},{"month":12,"riseRate":0.166667,"avgChangeRate":-0.054912}],"exchange":"SEHK","name":"BEIGENE","nameEN":"BEIGENE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BEIGENE(06160),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BEIGENE(06160) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BEIGENE,06160,BEIGENE股票,BEIGENE股票老虎,BEIGENE股票老虎国际,BEIGENE行情,BEIGENE股票行情,BEIGENE股价,BEIGENE股市,BEIGENE股票价格,BEIGENE股票交易,BEIGENE股票购买,BEIGENE股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BEIGENE(06160),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BEIGENE(06160) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}